• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer

byNeel MistryandTeddy Guo
August 15, 2023
in Chronic Disease, Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group.

2. Patients assigned to atezolizumab had fewer treatment-related adverse events and treatment-related deaths.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Prior first-line trials in advanced non-small-cell lung cancer (NSCLC) lacked representation for older or patients with reduced fitness. Data surrounding treatment safety and efficacy for advanced NSCLC remains scarce. This randomized controlled trial aimed to compare the safety and efficacy of atezolizumab monotherapy with single-agent chemotherapy for patients with NSCLC who were ineligible for platinum-based chemotherapy. The primary outcome of this study was improved overall survival with atezolizumab compared to chemotherapy, while key secondary outcomes included enhanced quality of life and fewer adverse events with atezolizumab. According to study results, atezolizumab was associated with a significant mortality benefit along with quality-of-life preservation and a favorable safety profile. Although this study was well done, it was limited by selection bias, thus skewing the validity of the results.

Click to read the study in The Lancet

Relevant Reading: First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

RELATED REPORTS

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

In-depth [randomized-controlled trial]: Between Sept 11, 2017, and Sept 23, 2019, 843 patients were screened for eligibility across 91 sites in 23 countries. Included were patients with stage IIIB or IV NSCLC ineligible for platinum-based chemotherapy or those ≥ 70 years old with ECOG 0-1 with substantial comorbidities. Altogether, 453 patients (302 to atezolizumab and 151 to chemotherapy) were included in the final analysis. The primary outcome of overall survival was greater in atezolizumab (median overall survival 10.3 months, 95% confidence interval [CI] 9.4-11.9) compared to chemotherapy (median overall survival 9.2 months, 95% CI 5.9-11.2, stratified hazard ratio [HR] 0.78, p=0.028). The 2-year survival rate with atezolizumab was 24% (95% CI 19.3-29.4) versus 12% (95% CI 6.7-18.0) with chemotherapy. Patients assigned to atezolizumab had fewer treatment-related adverse events and treatment-related deaths (16% and 1%, respectively) versus placebo (33% and 3%, respectively). Overall, findings from this study suggest that atezolizumab monotherapy presents a promising first-line treatment alternative for advanced NSCLC patients.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Atezolizumabchemotherapylung cancernon-small cell lung cancer (NSCLC)pulmonologyrespirology
Previous Post

Trigger-specific syncope in patients with long QT syndrome associated with differential risk of subsequent life-threatening events and response to therapy

Next Post

Virtual reality treatment may be helpful in treating anxiety disorders

RelatedReports

Patient Basics: Lung Cancer Overview
AI Roundup

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

June 23, 2025
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

June 19, 2025
Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 9, 2025

June 9, 2025
Next Post
Quick Take: Prevalence and Treatment of Depression, Anxiety, and Conduct Problems in US Children

Virtual reality treatment may be helpful in treating anxiety disorders

#VisualAbstract: Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT)

#VisualAbstract: Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT)

Orforglipron may be a safe and effective oral GLP-1 agonist for treatment of type 2 diabetes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.